DiaMedica Therapeutics Inc. (DMAC) Reports Q3 Loss of $0.20/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to DiaMedica Therapeutics Inc. (DMAC) Reports Q3 Loss of $0.20/Share

DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

November 13, 2019 4:12 PM EST

Phase II Study of DM199 in Chronic Kidney Disease Commences Screening REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment Management Team Strengthens with Sydney Gilman, Ph.D., Vice President of Regulatory Affairs Conference Call with Management Tomorrow, November 14 at 7am CT

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and reported its financial... More